On October 9, 2023 Amplia Therapeutics reported that poster presentation delivered by Professor Dwayne Stupack from the University of California, San Diego at the AACR (Free AACR Whitepaper) Special Conference in Cancer Research: Ovarian Cancer has shared the findings of new preclinical studies that support the potential of our FAK inhibitor, narmafotinib (AMP945), in the treatment of high-grade serous ovarian cancer (Press release, Amplia Therapeutics, OCT 9, 2023, View Source [SID1234635714]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data shows that narmafotinib is active in mouse models of ovarian cancer, with improved activity and tolerability compared to PARP inhibitors – the current standard-of-care. Furthermore, it shows promising activity in a model unresponsive to these inhibitors. This builds on Prof. Stupack’s previous research demonstrating that inhibition of the FAK enzyme can make chemotherapy and immunotherapy more effective in tough-to-treat ovarian cancers.

Each year over 1000 women in Australia die from ovarian cancer, indicating a clear need for better treatments.

Amplia CEO and MD, Dr Chris Burns, commented:

"The research results presented today by Prof. Stupack are extremely exciting and clearly demonstrate that our best-in-class FAK inhibitor narmafotinib has significant potential in the treatment of ovarian cancer."